Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tretazicar/caricotamide

Next Previous
Drug Profile

Tretazicar/caricotamide

Alternative Names: CB 1954; EP 0152R; Prolarix

Latest Information Update: 19 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protherics
  • Developer BTG
  • Class Antineoplastics; Aziridines
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Liver cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Sep 2009 Discontinued - Phase-II for Liver cancer in Belgium (IV)
  • 06 May 2009 Tretazicar/caricotamide is available for licensing in (http://www.btgplc.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top